Lilly agrees to cut Zepbound prices and set a $50 Medicare copay

Eli Lilly said Nov. 6 that it agreed with the Trump administration to lower prices for its obesity medicines, including Zepbound, and to offer Medicare beneficiaries a monthly copay of no more than $50 ^[1]. In return, Lilly will receive three years of relief from tariffs on its drugs and will not face future pricing mandates, the company said ^[1].

What the agreement covers

Lilly said that starting as early as April 1, 2026, Medicare beneficiaries would pay no more than $50 a month for Zepbound (tirzepatide), sold in a multi-dose pen, and for orforglipron, its once-daily obesity pill, provided both are approved by the Food and Drug Administration ^[1]. States would also be able to expand access to both through Medicaid ^[1].

BioPharma Dive reported the deal from the White House announcement as making Zepbound and Novo Nordisk's Wegovy available to some Medicare enrollees for $245 a month, with those who qualify paying a $50 monthly copay ^[2]. That article says the Medicare price would come through a pilot program covering most beneficiaries, but that the law authorizing Medicare drug coverage specifically bars weight-loss products, which may limit which beneficiaries qualify and could give the program a fixed expiration date ^[2]. The two accounts describe the Medicare terms differently: Lilly's release states a $50 monthly figure for beneficiaries, while BioPharma Dive reports a $245 monthly price alongside the $50 copay ^[1][2].

For people paying cash, Lilly said the Zepbound multi-dose pen will be $299 at its lowest dose, with higher doses up to $449 — a $50 discount to current direct-to-patient prices — through LillyDirect's self-pay pharmacy channel once approved ^[1]. Orforglipron would start at $149 for the lowest dose and go up to $399 ^[1]. BioPharma Dive reported the current direct-to-consumer monthly charge is $499, and that list prices are $1,080 for Zepbound and $1,350 for Wegovy ^[2].

Lilly said the agreement does not include pricing obligations in the commercial channel ^[1]. An analyst team cited by BioPharma Dive estimates the average U.S. commercial plan pays about $450 to $500 a month for Zepbound, and wrote that Lilly said it “does not have any obligations” to cut those prices ^[2].

The deal also adds Emgality (galcanezumab-gnlm), Trulicity (dulaglutide) and Mounjaro (tirzepatide) to LillyDirect at 50% to 60% off their current list prices, and keeps Lilly's insulin out-of-pocket cap at $35 a month ^[1].

Why it matters for patients

None of the price changes are in effect yet. The earliest Medicare start date Lilly gave is April 1, 2026, and that depends on FDA approvals ^[1].

Whether a patient's cost changes depends on how they get the drug. Medicare beneficiaries with obesity or overweight could see a set monthly copay ^[1], but the deal does not apply to the vast majority of people who receive their medicines through commercial insurance ^[2]. Lilly said the agreement would improve access for nearly 40 million Americans with obesity on government insurance programs, plus millions more who pay out of pocket ^[1].

The two accounts also differ on how broad the Medicare piece will be. Lilly describes access for beneficiaries generally ^[1], while BioPharma Dive reports that because Medicare's drug law bars weight-loss products, the pilot likely limits which beneficiaries qualify and may have a fixed end date ^[2]. Which specific patients will qualify has not been disclosed.

What happens next

April 1, 2026 is the earliest date Lilly gives for Medicare beneficiaries to pay no more than $50 a month, contingent on FDA approvals ^[1].

Lilly applied for a Commissioner's National Priority Voucher for orforglipron, which could accelerate FDA review ^[1]. The FDA awarded national priority vouchers to Wegovy and to orforglipron, which could shorten regulatory reviews ^[2]. Lilly is running Phase 3 studies of orforglipron for type 2 diabetes and for weight management in adults with obesity or overweight who have at least one weight-related medical problem ^[1].

Novo Nordisk expects a negative “low single-digit impact” on global sales growth in 2026, when the new prices are expected to be implemented ^[2]. Lilly did not specify how its sales might be affected ^[2].